Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia

NCT00536341 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT00536341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00536341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2016
Enrollment
64 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia